HLS Therapeutics (TSX:HLS) Other Long-Term Liabilities: C$2.23 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:HLS HLS Therapeutics Inc TSX:HLS
65 GF Score
Price C$4.03
GF Value C$4.49
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is HLS Therapeutics Other Long-Term Liabilities?

HLS Therapeutics TSX:HLS +0.75% 65 Other Long-Term Liabilities is C$2.23 Mil as of Mar. 2026. GuruFocus rates TSX:HLS with a GF Score™ of 65/100 and a GF Value™ of C$4.49 (Modestly Undervalued). The stock has 4 warning signs investors should review.

HLS Therapeutics's other long-term liabilities for the quarter that ended in Mar. 2026 was C$2.23 Mil.

HLS Therapeutics's quarterly other long-term liabilities declined from Sep. 2025 (C$2.45 Mil) to Dec. 2025 (C$2.31 Mil) and declined from Dec. 2025 (C$2.31 Mil) to Mar. 2026 (C$2.23 Mil).

HLS Therapeutics's annual other long-term liabilities declined from Dec. 2023 (C$2.37 Mil) to Dec. 2024 (C$1.11 Mil) but then increased from Dec. 2024 (C$1.11 Mil) to Dec. 2025 (C$2.31 Mil).

HLS Therapeutics Other Long-Term Liabilities Related Terms

HLS Therapeutics Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for HLS Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HLS Therapeutics Other Long-Term Liabilities Chart

HLS Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.41 1.11 2.37 1.11 2.31

HLS Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.62 1.88 2.45 2.31 2.23
TSX:HLS
65GF Score
HLS Therapeutics Inc TSX:HLS
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HLS Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of C$2.23 Mil mean?
HLS Therapeutics (TSX:HLS) has a Other Long-Term Liabilities of C$2.23 Mil as of Mar. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on HLS Therapeutics and its competitors.
Is HLS Therapeutics' Other Long-Term Liabilities too high?
HLS Therapeutics' current Other Long-Term Liabilities is C$2.23 Mil. Overall, HLS Therapeutics has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does HLS Therapeutics' Other Long-Term Liabilities compare to ZTS?
HLS Therapeutics' Other Long-Term Liabilities of C$2.23 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on HLS Therapeutics and its competitors. HLS Therapeutics's current Other Long-Term Liabilities is C$2.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HLS Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, HLS Therapeutics (TSX:HLS) is currently considered Modestly Undervalued. The stock's GF Value™ is C$4.49, compared to a current price of C$4.03 — trading 10.2% below its estimated fair value. The current Other Long-Term Liabilities is C$2.23 Mil. HLS Therapeutics' overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For HLS Therapeutics (TSX:HLS), the current Other Long-Term Liabilities is C$2.23 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HLS Therapeutics (TSX:HLS) Overvalued in 2026?

Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued. The current stock price of C$4.03 is trading 10.2% below its estimated GF Value™ of C$4.49. GuruFocus considers HLS Therapeutics to be Modestly Undervalued.

Key valuation signals for TSX:HLS:

  • Other Long-Term Liabilities: C$2.23 Mil
  • GF Value™: C$4.49 vs. price of C$4.03 (10.2% below fair value)
  • GF Score™: 65/100 with 4 warning signs

No single metric tells the full story. See the TSX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HLS Therapeutics Business Description

Other Exchanges HLTRF:USA74D:Germany
Address 10 Carlson Court, Suite 701, Etobicoke, Toronto, ON, CAN, M9W 6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
65GF Score

Get the complete analysis for TSX:HLS

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$4.03
Price
C$4.49
GF Value